July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

The model suggests that negative KRAS findings are believable when the maximum of APC and TP53 frequencies is at least 8% (corresponding posterior probability of false negative <5%). Validation ...

Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Supported in part by the United States Department of Veterans Affairs, Veterans ...

Several factors — most notably, older age, treatment in the community setting , and a lower educational level in the area of residence — are associated with lower rates of microsatellite instability ...

Please provide your email address to receive an email when new articles are posted on . Less than half of patients received MSI testing and about one-quarter received KRAS testing. Older age, rural ...

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments. Genetic testing is a laboratory method ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

A small molecule that blocks mutants of the protein KRas could guide drugmakers to new treatments for cancers associated with these proteins. In tests with cells, the molecule, known as BI-2865, acted ...